{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/hum-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/hum-stock-analysis/data.json",
 "title": "Humana Inc (HUM) Stock Forecast & Price Target (2026)",
 "description": "Humana Inc. (HUM) stock: Healthcare, Healthcare Plans. $47.8B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Humana Inc. (HUM)",
 "published": "2026-07-10T09:23:37+00:00",
 "modified": "2026-09-27T04:11:18.409+00:00",
 "generated": "2026-09-27T15:53:28.093Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "HUM",
  "name": "Humana Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Healthcare Plans",
  "country": "United States",
  "website": "https://www.humana.com"
 },
 "quote": {
  "price": 397.93,
  "previousClose": 380.32,
  "change": 17.61,
  "changePercent": 4.63,
  "open": 389.70001,
  "high": 413.57001,
  "low": 386.70999,
  "volume": 1938500,
  "averageVolume": 1054760,
  "marketCap": 47783555761,
  "fiftyTwoWeekHigh": 428.88,
  "fiftyTwoWeekLow": 163.11,
  "marketOpen": false,
  "asOf": "2026-09-27T04:11:18.000Z"
 },
 "statistics": {
  "pe": 37.647114,
  "eps": 10.57,
  "dividendYield": 0.008891567971728182,
  "beta": 0.745,
  "priceToSales": 0.32800576,
  "priceToBook": 2.4870467,
  "revenueTtm": 145679007744,
  "grossMargin": null,
  "returnOnEquity": 0.06893
 },
 "technicals": {
  "rsi": 47.79,
  "macd": -1.13,
  "sma50": 386.74,
  "sma200": 290.2,
  "rsiSignal": "Neutral",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bearish",
  "rating": "Neutral"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 415,
  "analystTarget": 415,
  "analystCount": 26,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T04:11:18.000Z",
  "priceAtAnalysis": 397.92999,
  "volatility": {
   "daily": 1.66,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 393.95,
  "aggressiveEntry": 397.93,
  "stopLoss": 352.9,
  "stopLossPercent": 10.42,
  "targets": [
   405.77,
   413.65,
   425.47
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 273.78,
    "base": 429.08,
    "upside90th": 672.47
   },
   {
    "year": 2028,
    "downside10th": 245.08,
    "base": 462.67,
    "upside90th": 873.44
   },
   {
    "year": 2029,
    "downside10th": 229.1,
    "base": 498.89,
    "upside90th": 1086.39
   },
   {
    "year": 2030,
    "downside10th": 219.02,
    "base": 537.95,
    "upside90th": 1321.31
   },
   {
    "year": 2031,
    "downside10th": 212.4,
    "base": 580.06,
    "upside90th": 1584.17
   },
   {
    "year": 2032,
    "downside10th": 208.08,
    "base": 625.47,
    "upside90th": 1880.1
   },
   {
    "year": 2033,
    "downside10th": 205.43,
    "base": 674.44,
    "upside90th": 2214.18
   },
   {
    "year": 2034,
    "downside10th": 204.06,
    "base": 727.24,
    "upside90th": 2591.74
   },
   {
    "year": 2035,
    "downside10th": 203.71,
    "base": 784.17,
    "upside90th": 3018.6
   },
   {
    "year": 2036,
    "downside10th": 204.21,
    "base": 845.56,
    "upside90th": 3501.1
   }
  ]
 },
 "faqCount": 8,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "HUM Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$389.70",
    "Day Range": "$386.71 to $413.57",
    "Prev Close": "$380.32",
    "Volume": "1.94M",
    "52-Week Range": "$163.11 to $428.88",
    "Market Cap": "$47.78B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (18% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "HUM Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, HUM beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "HUM Analysis",
   "text": [
    "At 47.79, the RSI for Humana Inc. (HUM) indicates neutral momentum, suggesting neither overbought nor oversold conditions. The stock is trading above its 50-day and 200-day moving averages ($386.74 and $290.20), as well as its 20-day EMA ($388.51), signaling an overall upward trend. MACD is slightly negative at -1.13, indicating a potential short-term bearish divergence, but this is counteracted by the positive positioning relative to key moving averages. Volume has been notably strong, with the latest volume of 1.94 million shares being 83.8% above the average, suggesting increased investor interest. Key support levels are found around the 50-day SMA of $386.74, while resistance may emerge near the current price or previous highs. The current technical setup suggests a consolidation phase with potential for a breakout, contingent on broader market sentiment and company-specific news.",
    "Insiders have made net purchases totaling $1.6 million with no reported sales, indicating strong confidence in the company's future prospects.",
    "The company reported a significant 26.2% revenue growth, outpacing the sector average and demonstrating strong market demand for its services.",
    "Humana Inc. beat EPS estimates by 8.71% in the quarter ending June 2026, leading to a slight positive price reaction.",
    "The majority of analysts rate Humana Inc. as 'Hold', with only a few 'Buy' ratings and one 'Sell', suggesting a lack of strong conviction for immediate upside.",
    "Humana Inc.'s P/E ratio of 37.65 is higher than the healthcare sector median of 31.9, potentially limiting upside if earnings growth does not accelerate.",
    "The base case outlook for Humana Inc. (HUM) suggests a modest upside to its median analyst price target of $415.00, implying a potential gain of 4.3% from the current price of $397.93. The company's strong revenue growth and positive insider sentiment provide a supportive backdrop. However, the mixed Wall Street consensus and relatively narrow upside limit immediate bullish conviction. Upside potential could be realized if the company demonstrates improved profit margins or exceeds forward earnings expectations, particularly given the projected strong EPS growth for next year. Conversely, a failure to improve profitability, increased regulatory scrutiny within the healthcare sector, or intensified competition could pressure the stock. The current valuation, while higher than the sector median P/E, is somewhat supported by its strong revenue growth, but any significant deterioration in margins would be a key bearish catalyst."
   ],
   "lists": {
    "ProTips": [
     "Consider the narrow upside to the median analyst price target of $415.00, suggesting limited immediate appreciation potential.",
     "Monitor upcoming earnings reports for signs of margin improvement, as current profit margins are below sector averages.",
     "Given the 'Hold' consensus and mixed technicals, consider position sizing carefully and potentially waiting for a clearer trend signal or a more compelling entry point."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Strong Insider Buying Activity",
     "text": "Insiders have made net purchases totaling $1.6 million with no reported sales, indicating strong confidence in the company's future prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Bullish",
     "title": "Strong Revenue Growth",
     "text": "The company reported a significant 26.2% revenue growth, outpacing the sector average and demonstrating strong market demand for its services.",
     "source": "Company Financials"
    },
    {
     "type": "Bullish",
     "title": "Positive Earnings Surprise in Latest Quarter",
     "text": "Humana Inc. beat EPS estimates by 8.71% in the quarter ending June 2026, leading to a slight positive price reaction.",
     "source": "Earnings Report"
    },
    {
     "type": "Bearish",
     "title": "Mixed Wall Street Consensus",
     "text": "The majority of analysts rate Humana Inc. as 'Hold', with only a few 'Buy' ratings and one 'Sell', suggesting a lack of strong conviction for immediate upside.",
     "source": "Analyst Ratings"
    },
    {
     "type": "Bearish",
     "title": "Valuation Premium Relative to Sector P/E",
     "text": "Humana Inc.'s P/E ratio of 37.65 is higher than the healthcare sector median of 31.9, potentially limiting upside if earnings growth does not accelerate.",
     "source": "Company Financials & Sector Data"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Humana Inc. (HUM) exhibits a Price-to-Earnings ratio of 37.65, which is above the healthcare sector median of 31.9, suggesting a premium valuation. Its Price-to-Sales ratio stands at 0.33, which is below the sector median of 3.7, indicating that the company is valued more attractively on a sales basis. The company's return on equity is 6.89%, which is in line with the sector median of 6.9%, but its net profit margin of 0.88% and operating margin of 3.46% are below the sector averages. Despite the higher P/E ratio, the company's strong revenue growth of 26.2% provides some justification. The debt-to-equity ratio of 0.76 is within reasonable bounds for the sector. The current valuation appears somewhat stretched given the modest profit margins, but the strong revenue expansion and positive insider buying could support continued performance. Investors should monitor future earnings reports for signs of margin improvement to justify the current valuation.",
    "Humana Inc. (HUM) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $7.61, beating the estimate of $7.00 by 8.71%, and the stock saw a 0.34% price increase. Prior to this, the March 2026 quarter saw an EPS of $10.31, slightly beating the estimate of $10.20, though the stock declined 2.75%. The company has a history of mixed earnings performance, with a significant loss reported for the December 2025 quarter, but has generally managed to meet or exceed analyst expectations in recent periods. Forward estimates suggest a negative EPS for the upcoming September and December 2026 quarters, but a strong rebound is projected for 2027.",
    "Humana Inc. (HUM) faces several key risks, including its elevated P/E ratio of 37.65 compared to the sector median of 31.9, suggesting potential valuation concerns. The narrow upside of 4.3% to the median analyst price target of $415.00 indicates limited immediate upside potential. Also, the company's profit margins (0.88% net, 3.46% operating) are below sector averages, which could limit its ability to absorb unexpected cost increases or competitive pressures."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "47.78B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "37.65"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "10.57"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.89%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "428.88"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "163.11"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Neutral RSI Neutral SMA Cross Bullish Price vs SMA Bullish MACD Bearish Golden Cross in effect with the 50-day SMA ($386.74) above the 200-day SMA ($290.20), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Neutral",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "47.79"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-1.13"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "386.74"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "290.20"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.14",
    "Correlation with Nasdaq 100 (QQQ)": "+0.09",
    "Correlation with Bitcoin (BTC)": "+0.27",
    "Correlation with Gold (XAU)": "-0.05"
   }
  },
  {
   "id": "trade-plans",
   "title": "HUM Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (47.8) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$405.77",
    "TARGET 2": "$413.65",
    "TARGET 3": "$425.47",
    "STOP LOSS": "$352.90"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "-3.55%",
    "Average Feb return": "-1.25%",
    "Average Mar return": "-2.17%",
    "Average Apr return": "+6.48%",
    "Average May return": "+4.38%",
    "Average Jun return": "+3.10%",
    "Average Jul return": "-0.15%",
    "Average Aug return": "+3.16%",
    "Average Sep return": "-4.08%",
    "Average Oct return": "+4.93%",
    "Average Nov return": "+3.52%",
    "Average Dec return": "-2.53%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.66%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in HUM in September 2016 would be worth about $22,454 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HUM today could grow to about $21,249 by 2036 in the base case, with a bull case near $87,983 and a bear case around $5,132. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "HUM Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $538 for HUM by 2030 in the base case, from $398 today (1.4x over 4 years). The downside path ends near $219. These are outcomes of a Monte Carlo simulation run on HUM's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using HUM's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "HUM simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$274",
        "$429",
        "$672"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$245",
        "$463",
        "$873"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$229",
        "$499",
        "$1,086"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$219",
        "$538",
        "$1,321"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$212",
        "$580",
        "$1,584"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$208",
        "$625",
        "$1,880"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$205",
        "$674",
        "$2,214"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$204",
        "$727",
        "$2,592"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$204",
        "$784",
        "$3,019"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$204",
        "$846",
        "$3,501"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "BDX Becton Dickinson and Co NYSE $183.82 +2.56%",
     "url": "https://clearank.com/stock/bdx-stock-analysis/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $675.00 -0.50%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "WST West Pharmaceutical Services Inc. NYSE $370.44 -0.85%",
     "url": "https://clearank.com/stock/wst-stock-analysis/"
    },
    {
     "text": "FBRX Forte Biosciences, Inc. NASDAQ $76.99 +0.00%",
     "url": "https://clearank.com/stock/fbrx-stock-analysis/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $148.78 +0.54%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "CVS CVS Health Corporation NYSE $89.13 +4.80%",
     "url": "https://clearank.com/stock/cvs-health-cvs/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $519.26 +1.14%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    },
    {
     "text": "CNC Centene Corp. NYSE $61.82 -0.16%",
     "url": "https://clearank.com/stock/centene-cnc/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare HUM",
   "links": [
    {
     "text": "ELV vs HUM Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/elv-vs-hum/"
    },
    {
     "text": "ADI vs TXN Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/adi-vs-txn/"
    },
    {
     "text": "CSX vs NSC Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/csx-vs-nsc/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "HUM Insider Trading Analysis",
   "facts": {
    "Bought": "$1.6M",
    "Sold": "None",
    "Insiders": "17",
    "Avg Transaction": "$823.5K"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in HUM",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 4, 2020",
       "cells": [
        "BROUSSARD BRUCE D. Chief Executive Officer",
        "Sell",
        "64.6K",
        "$29.1M"
       ]
      },
      {
       "label": "Nov 5, 2021",
       "cells": [
        "BROUSSARD BRUCE D. Chief Executive Officer",
        "Sell",
        "50.0K",
        "$22.7M"
       ]
      },
      {
       "label": "Nov 5, 2020",
       "cells": [
        "KANE BRIAN A Chief Financial Officer",
        "Sell",
        "49.2K",
        "$21.9M"
       ]
      },
      {
       "label": "Nov 3, 2022",
       "cells": [
        "WHEATLEY TIMOTHY ALAN Officer",
        "Sell",
        "22.6K",
        "$12.8M"
       ]
      },
      {
       "label": "Feb 23, 2021",
       "cells": [
        "BROUSSARD BRUCE D. Chief Executive Officer",
        "Sell",
        "27.5K",
        "$10.4M"
       ]
      },
      {
       "label": "Feb 27, 2023",
       "cells": [
        "BROUSSARD BRUCE D. Chief Executive Officer",
        "Sell",
        "17.6K",
        "$8.9M"
       ]
      },
      {
       "label": "Feb 22, 2019",
       "cells": [
        "BROUSSARD BRUCE D. Chief Executive Officer",
        "Sell",
        "24.4K",
        "$7.6M"
       ]
      },
      {
       "label": "Dec 21, 2022",
       "cells": [
        "JONES DAVID A JR Director",
        "Sell",
        "15.0K",
        "$7.5M"
       ]
      },
      {
       "label": "Feb 25, 2019",
       "cells": [
        "BILNEY JODY L Officer",
        "Sell",
        "23.3K",
        "$7.2M"
       ]
      },
      {
       "label": "Nov 4, 2020",
       "cells": [
        "WHEATLEY TIMOTHY ALAN Officer",
        "Sell",
        "15.3K",
        "$6.8M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Humana+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Humana Inc.'s current stock price and consensus rating?",
   "answer": "Humana Inc. (HUM) is currently trading at $397.93. The consensus rating is 'Hold', supported by a consensus score of 59 out of 100."
  },
  {
   "question": "Is Humana Inc. stock a buy right now?",
   "answer": "The current consensus rating for Humana Inc. (HUM) is 'Hold', with a consensus score of 59. While insider activity is positive, the stock's valuation and mixed analyst sentiment suggest a cautious approach."
  },
  {
   "question": "What is Humana Inc.'s price target from Wall Street analysts?",
   "answer": "The median price target for Humana Inc. (HUM) from Wall Street analysts is $415.00, offering a potential upside of 4.3% from the current price of $397.93."
  },
  {
   "question": "How is Humana Inc. performing technically?",
   "answer": "Technically, Humana Inc. (HUM) is trading above its 50-day and 200-day moving averages ($386.74 and $290.20), with a neutral RSI at 47.8. Volume is strong, indicating investor interest, but MACD shows slight bearish momentum."
  },
  {
   "question": "What are the key financial metrics for Humana Inc. compared to its sector?",
   "answer": "Humana Inc. (HUM) has a P/E of 37.65 versus the sector median of 31.9, and a revenue growth of 26.2% compared to the sector's 8.1%. Its profit margins are below sector averages, while its ROE is in line."
  },
  {
   "question": "What is Humana Inc.'s stock forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Humana Inc.'s (HUM) stock forecast for 2030 shows a base case price of $537.95, with a downside projection of $219.02 and an upside projection of $1321.31. These are statistical outcomes, not guarantees."
  },
  {
   "question": "Are there any significant insider transactions for Humana Inc. recently?",
   "answer": "Yes, Humana Inc. (HUM) insiders are net sellers, with $1.6 million in total purchases and no reported sales in recent filings. The insider verdict is a 'Moderate Buy Signal'."
  },
  {
   "question": "What is Humana Inc.'s dividend yield?",
   "answer": "Humana Inc. (HUM) offers a dividend yield of approximately 0.89%, with a dividend rate of $3.54."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "BDX",
    "name": "Becton Dickinson and Co NYSE",
    "price": "$183.82",
    "change": "+2.56%",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$675.00",
    "change": "-0.50%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "WST",
    "name": "West Pharmaceutical Services Inc. NYSE",
    "price": "$370.44",
    "change": "-0.85%",
    "url": "https://clearank.com/stock/wst-stock-analysis/"
   },
   {
    "ticker": "FBRX",
    "name": "Forte Biosciences, Inc. NASDAQ",
    "price": "$76.99",
    "change": "+0.00%",
    "url": "https://clearank.com/stock/fbrx-stock-analysis/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$148.78",
    "change": "+0.54%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "CVS",
    "name": "CVS Health Corporation NYSE",
    "price": "$89.13",
    "change": "+4.80%",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$519.26",
    "change": "+1.14%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "CNC",
    "name": "Centene Corp. NYSE",
    "price": "$61.82",
    "change": "-0.16%",
    "url": "https://clearank.com/stock/centene-cnc/"
   }
  ],
  "comparisons": [
   {
    "ticker": "ELV vs HUM Comparison",
    "name": "",
    "url": "https://clearank.com/compare/elv-vs-hum/"
   },
   {
    "ticker": "ADI vs TXN Comparison",
    "name": "",
    "url": "https://clearank.com/compare/adi-vs-txn/"
   },
   {
    "ticker": "CSX vs NSC Comparison",
    "name": "",
    "url": "https://clearank.com/compare/csx-vs-nsc/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EXC",
    "text": "Exelon Corp.",
    "url": "https://clearank.com/stock/exc-stock-analysis/"
   },
   {
    "ticker": "GWW",
    "text": "W.W. Grainger Inc.",
    "url": "https://clearank.com/stock/gww-stock-analysis/"
   },
   {
    "ticker": "CDE",
    "text": "Coeur Mining Inc.",
    "url": "https://clearank.com/stock/cde-stock-analysis/"
   },
   {
    "ticker": "CCI",
    "text": "Crown Castle Inc.",
    "url": "https://clearank.com/stock/cci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "BE",
    "text": "↑ 8.27%",
    "url": "https://clearank.com/stock/be-stock-analysis/"
   },
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 8.20%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "CI",
    "text": "The Cigna Group",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "CNC",
    "text": "Centene Corporation",
    "url": "https://clearank.com/stock/centene-cnc/"
   },
   {
    "ticker": "CVS",
    "text": "CVS Health",
    "url": "https://clearank.com/stock/cvs-health-cvs/"
   },
   {
    "ticker": "ELV",
    "text": "Elevance Health",
    "url": "https://clearank.com/stock/elv-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "text": "Molina Healthcare Inc.",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/HUM-humana-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/HUM-humana-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "Humana (HUM) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/hum-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/hum-stock-analysis/",
        "name": "Humana Inc (HUM) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/hum-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/hum-stock-analysis/",
     "name": "Humana Inc (HUM) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-10T09:23:37+00:00",
     "dateModified": "2026-09-27T04:11:18+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/HUM-humana-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/hum-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/hum-stock-analysis/#richSnippet",
     "headline": "Humana Inc (HUM) Stock Forecast & Price Target (2026)",
     "name": "Humana Inc (HUM) Stock Forecast & Price Target (2026)",
     "description": "Humana Inc. (HUM) stock: Healthcare, Healthcare Plans. $47.8B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-10T09:23:37+00:00",
     "dateModified": "2026-09-27T04:11:18+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Humana Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "HUM"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Humana Inc. is a managed healthcare company that provides health insurance and healthcare services across the United States. Its core offerings include Medicare Advantage plans, stand-alone prescription drug coverage, Medicare Supplement products, Medicaid-related plans, specialty benefits such as d",
      "tickerSymbol": "HUM",
      "sameAs": "https://www.humana.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/hum-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/HUM-humana-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/hum-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Humana Inc.'s current stock price and consensus rating?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Humana Inc. (HUM) is currently trading at $397.93. The consensus rating is 'Hold', supported by a consensus score of 59 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "Is Humana Inc. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The current consensus rating for Humana Inc. (HUM) is 'Hold', with a consensus score of 59. While insider activity is positive, the stock's valuation and mixed analyst sentiment suggest a cautious approach."
     }
    },
    {
     "@type": "Question",
     "name": "What is Humana Inc.'s price target from Wall Street analysts?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The median price target for Humana Inc. (HUM) from Wall Street analysts is $415.00, offering a potential upside of 4.3% from the current price of $397.93."
     }
    },
    {
     "@type": "Question",
     "name": "How is Humana Inc. performing technically?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Technically, Humana Inc. (HUM) is trading above its 50-day and 200-day moving averages, with a neutral RSI of 47.79. Volume is strong, indicating investor interest, but MACD shows slight bearish momentum."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key financial metrics for Humana Inc. compared to its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Humana Inc. (HUM) has a P/E of 37.65 versus the sector median of 31.9, and a revenue growth of 26.2% compared to the sector's 8.1%. Its profit margins are below sector averages, while its ROE is in line."
     }
    },
    {
     "@type": "Question",
     "name": "What is Humana Inc.'s stock forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Humana Inc.'s (HUM) stock forecast for 2030 shows a base case price of $537.95, with a downside projection of $219.02 and an upside projection of $1321.31. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant insider transactions for Humana Inc. recently?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Yes, Humana Inc. (HUM) insiders are net buyers, with $1.6 million in total purchases and no reported sales across 39 transactions. The insider verdict is a 'Moderate Buy Signal'."
     }
    },
    {
     "@type": "Question",
     "name": "What is Humana Inc.'s dividend yield?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Humana Inc. (HUM) offers a dividend yield of approximately 0.89%, with a dividend rate of $3.54."
     }
    }
   ]
  }
 ]
}